Screening method finds potential drugs to repurpose against COVID-19
Researchers have identified 38 drugs that could be repurposed to treat COVID-19 through a strategy involving virtual screening and cell-based assays.
List view / Grid view
Researchers have identified 38 drugs that could be repurposed to treat COVID-19 through a strategy involving virtual screening and cell-based assays.
A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived cell lines are limited as a pre-clinical model – in part because of an altered metabolic poise. A recent study has revealed a profound plasticity in gene expression and metabolic poise that can…
28 May 2021 | By Eurofins DiscoverX* and Tecan
In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
The global cell-based assays market is expected to grow due to increasing investments into cell-based research and a rise in chronic diseases.
The length of time between the administration of a COVID-19 vaccine and evidence of a robust immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) means that treatments are still required. In this article, Sheraz Gul and Alp Tegin Sahin explore the various therapeutic targets that have been identified…
In this ebook, find articles exploring some of the assays used to identify the most promising COVID-19 drugs and discussing the development of a novel assay to reveal potential peptide therapeutics for cancer.
New research has shown that the cell-based assays market will grow at a CAGR of 8.1 percent between 2020 and 2025.
Researchers have developed a cell-based assay for the discovery of new IDO1 inhibitors, overcoming challenges from cell-free assays.
A team has developed nanolitre cell assays on droplet microarrays to enable pharmacodynamic monitoring in live cells.
A team has developed enterocyte-like cells from hiPSCs, which can be used to study the absorption of novel oral drugs.
Researchers have uncovered a flaw in lab models used to study the human blood-brain barrier and a potential strategy to correct the error.
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.